Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus vaccine (Flubio)
- Development stage
- Phase 4
- Lead developer
- Bio Farma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Flubio is an inactivated trivalent influenza virus vaccine prepared from WHO-recommended prevalent strains of influenza virus types A and B. It helps the body develop immunity against influenza virus infection. The vaccine is specifically formulated for the Northern Hemisphere region.
- Brand names
- FlubioFlubio HL
- Other names
- Inactivated influenza HA vaccine (Flubio)Influenza HA trivalent vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on influenza virus vaccine (Flubio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus vaccine (Flubio).